Job Description
ABOUT US There are more than 9 million immunocompromised people in the United States. Almost half a million of those represent a population that are moderately to severely immunocompromised and at highest risk for severe COVID-19, including stem cell and solid organ transplant patients as well as those with hematologic cancers. At Invivyd , Inc., we take those numbers very seriously and we come to work each day on a mission to deliver protection from serious viral infectious diseases, beginning with SARS-CoV-2. Invivyd deploys a proprietary integrated technology platform unique in the industry designed to assess, monitor, develop, and adapt to create best in class antibodies. In March 2024 , Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) in its pipeline of innovative antibody candidates. In October 2025 , the FDA cleared the company's Investigational New Drug (IND) application and provided feedback to advance the company's REVOLUTION clinical program, Invivyd 's development program for VYD2311, a vaccine alternative monoclonal antibody being investigated for the prevention of COVID-19. Be part of making a difference. Be part of Invivyd . Location: Remote, US Position Summary: The National Account Director (NAD), Strategic IDNs & Integrated Health Systems serves as the primary customer-facing lead for institutional engagement, account management, and contracting execution across the country's largest national Integrated Delivery Networks (IDNs) and academic medical centers. The incumbent is responsible for leading contractual, market access, and operational engagement to understand procurement, secure access and align medical policy coverage with minimal restrictions. By assessing and diagnosing complex institutional environments, the NAD removes systemic barriers to patient onboarding, conversion, and adherence while ensuring disciplined financial management and portfolio optimization across the health system eco
